News Releases

Date Title and Summary Additional Formats
Jun 07, 2019
Jun 05, 2019
LabCorp Announces New Leadership Roles
David P. King , current chairman, president and CEO of LabCorp, to become executive chairman of the board of directors effective Nov. 1 , retiring Oct. 31 as president and CEO Adam H. Schechter , current lead independent director of LabCorp and longtime Merck executive, to become president and CEO
Jun 03, 2019
LabCorp Announces New Term Loan Facility
BURLINGTON, N.C. --(BUSINESS WIRE)--Jun. 3, 2019-- On June 3, 2019 , LabCorp® (NYSE: LH) entered into a new Term Loan Credit Agreement, which provides for a two-year term loan credit facility in the principal amount of $850 million (the “New Term Loan Facility”). Bank of America, N.A.
Jun 03, 2019
LabCorp and Envigo Complete Innovative Transactions
LabCorp Acquires Envigo’s Global Nonclinical Contract Research Business, Envigo Acquires LabCorp’s Covance Research Products Business BURLINGTON, N.C. & INDIANAPOLIS --(BUSINESS WIRE)--Jun. 3, 2019-- LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding
May 10, 2019
LabCorp Announces Availability of New QIAGEN therascreen FGFR mutation analysis companion diagnostic for Bladder Cancer
New Test Further Underscores LabCorp’s Leadership in Development and Commercialization of Innovative Lab Testing BURLINGTON, N.C. --(BUSINESS WIRE)--May 10, 2019-- LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced the
May 02, 2019
LabCorp to Webcast Its Annual Meeting of Shareholders
BURLINGTON, N.C. --(BUSINESS WIRE)--May 2, 2019-- LabCorp® (NYSE: LH) today announced that its Annual Meeting of Shareholders will be webcast live beginning May 9, 2019 , at 9:00 a.m. Eastern Daylight Time via the Company website at www.LabCorp.com . An archived replay of the audio webcast will be
Apr 30, 2019
LabCorp Announces 2019 First Quarter Results and Increases 2019 Earnings Guidance
Q1 revenue of $2.79 billion , down 2% from $2.85 billion last year Q1 diluted EPS of $1.86 , up 11% from $1.67 last year; Q1 adjusted EPS of $2.62 , down 6% from $2.78 last year 2019 adjusted EPS guidance increased to $11.05 to $11.45 , from $11.00 to $11.40 2019 free cash flow guidance of $950
Apr 17, 2019
LabCorp and Envigo Sign Innovative Agreement to Expand Covance’s Nonclinical Drug Development Capabilities and Create an Independent Research Models Provider
LabCorp will purchase Envigo’s nonclinical contract research services business, expanding the global reach and capabilities of Covance’s nonclinical drug development business Envigo’s research models and services business will purchase Covance’s research products business located in the United
Apr 01, 2019
LabCorp to Announce First Quarter Financial Results on April 30, 2019
BURLINGTON, N.C. --(BUSINESS WIRE)--Apr. 1, 2019-- LabCorp® (NYSE: LH) will release its first quarter of 2019 financial results before the market opens on Tuesday, April 30, 2019 , followed by a conference call and webcast beginning at 9:00 a.m. EDT to discuss the results.
Apr 01, 2019
Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021
BURLINGTON, N.C. --(BUSINESS WIRE)--Apr. 1, 2019-- LabCorp® (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject
Mar 28, 2019
LabCorp Earns 100 Percent on Human Rights Campaign Foundation’s 17th Annual Scorecard on LGBTQ Workplace Equality
Receives Designation as a Best Place to Work for LGBTQ Equality for Second Year in a Row BURLINGTON, N.C. --(BUSINESS WIRE)--Mar. 28, 2019-- LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced that it received a perfect
Mar 11, 2019
LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest
BURLINGTON, N.C. --(BUSINESS WIRE)--Mar. 11, 2019-- LabCorp® (NYSE: LH) announced today that for the period of March 11, 2019 to Sept. 10, 2019 , its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will accrue (subject to the terms of the Zero Coupon Notes) contingent cash
Mar 05, 2019
LabCorp is Scheduled to Present at the 2019 Barclays Global Healthcare Conference
BURLINGTON, N.C. --(BUSINESS WIRE)--Mar. 5, 2019-- LabCorp® (NYSE: LH) today announced it will participate at the 2019 Barclays Global Healthcare Conference . LabCorp’s presentation is planned for Tuesday, March 12, 2019 , at 8:30 a.m. (ET) . A live audio webcast of the presentation will be
Feb 19, 2019
Feb 07, 2019
LabCorp Announces 2018 Fourth Quarter and Full Year Results and Provides 2019 Guidance
Revenue: Q4 of $2.8 billion , up 2% over 2017; Full year of $11.3 billion , up 10% over 2017 Diluted EPS: Q4 of $1.56 ; Full year of $8.61 Adjusted EPS: Q4 of $2.52 , up 11% over 2017; Full year of $11.02 , up 20% over 2017 2019 Adjusted EPS guidance of $11.00 to $11.40 2019 Free Cash Flow guidance
Jan 22, 2019
LabCorp Named to FORTUNE Magazine's 2019 List of ‘World’s Most Admired Companies,’ Making the Annual List for the Second Consecutive Year
BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 22, 2019-- LabCorp® (NYSE: LH), a leading global life sciences company, today announced that it has been named to  FORTUNE  magazine's 2019 List of World’s Most Admired Companies, making the annual list for the second consecutive year.
Jan 16, 2019
LabCorp to Announce Fourth Quarter and Full Year 2018 Financial Results on February 7, 2019
BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 16, 2019-- LabCorp® (NYSE: LH) will release its fourth quarter and full year 2018 financial results before the market opens on Thursday, Feb. 7, 2019 , and then will host a conference call and webcast beginning at 9:00 a.m. EDT to discuss the results.
Jan 15, 2019
LabCorp and Texas Association of Community Health Centers Extend Agreement for LabCorp to Be Exclusive Laboratory for Community Health Centers Across Texas
LabCorp Will Provide Enhanced Laboratory Services, With an Emphasis on Chronic Diseases, for Clinics Serving More Than One Million Patients Annually BURLINGTON, N.C. & AUSTIN, Texas --(BUSINESS WIRE)--Jan. 15, 2019-- LabCorp® (NYSE: LH) a leading global life sciences company, and the Texas
Jan 03, 2019
Conversion Right Triggered For LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021
BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 3, 2019-- LabCorp® (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject
Jan 03, 2019
GENFIT and LabCorp Sign a Licensing Agreement to Expand Access to an Innovative Diagnostic Assay for Non-Alcoholic Steatohepatitis (NASH)
Multi-Biomarker Test Will Provide the Clinical Research Community with a Non-Invasive Tool to Identify and Monitor Patients with NASH and Significant Fibrosis LILLE, France & CAMBRIDGE, Mass. & BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 3, 2019-- LabCorp® (NYSE: LH), a leading global life sciences
Jan 02, 2019
LabCorp is Scheduled to Present at the 37th Annual J.P. Morgan Healthcare Conference
BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 2, 2019-- LabCorp® (NYSE: LH) today announced it will participate at the 37th Annual J.P. Morgan Healthcare Conference . LabCorp’s presentation is scheduled for Tuesday, January 8, 2019 at 1:30 p.m. (PT) , followed by a question and answer session at 2:00